BioVie(BIVI) - 2023 Q2 - Quarterly Report

Drug Development and Clinical Trials - BioVie has obtained Orphan Drug Designation for BIV201 (terlipressin) in the U.S. for treating hepatorenal syndrome and ascites, providing a potential seven-year marketing exclusivity[29]. - The company plans to complete the Phase 2b clinical development program for BIV201 and conduct a pivotal Phase 3 trial, alongside pursuing additional patent issuances[53]. - The company is developing NE3107, a drug targeting Alzheimer's Disease and Parkinson's Disease, with a Phase 3 study expected to complete in Q3 2023[65]. - The Phase 2 study of NE3107 in Parkinson's disease patients met its primary and secondary objectives, involving 45 patients treated over 28 days[66]. - The company’s Orphan drug candidate BIV201 is in a Phase 2b study for refractory ascites due to liver cirrhosis, with top-line results anticipated in mid-2023[68]. - The Company’s Orphan drug candidate BIV201 is being evaluated in a US Phase 2b study for the treatment of refractory ascites due to liver cirrhosis, with top-line results anticipated in mid-2023[187]. - The Company relies on third parties for clinical trials, which may affect the control over data quality and trial management[54]. - The Company relies on third parties for clinical trials, which may affect the timeline and success of product development if they do not meet contractual obligations[175]. - Health emergencies or pandemics may adversely affect clinical trials, supply chains, and the company's financial performance, potentially impacting its ability to raise funds[219]. - The company may experience delays in clinical trials if relationships with trial sites or contract research organizations (CROs) terminate[221]. Financial Performance and Management - The current portion of other liabilities was $338,698 as of December 31, 2022, down from $1.3 million in June 2022, indicating improved financial management[42]. - The company is facing financial constraints that may limit its ability to complete all planned clinical studies, highlighting the need for successful capital raises[53]. - As of December 31, 2022, the company had working capital of approximately $38.2 million and cash of approximately $45.7 million[70]. - The company reported an accumulated deficit of approximately $277.1 million and has not generated any revenue to date[70]. - The net loss for the six months ended December 31, 2022, was $26,102,713, compared to a net loss of $10,955,070 for the same period in 2021, reflecting a 138.5% increase in losses[81]. - The company reported a net cash used in operating activities of $17,229,548 for the six months ended December 31, 2022, compared to $7,240,891 in the prior year, indicating a 138.5% increase in cash outflow[84]. - Cash provided by financing activities was $44,336,423 for the six months ended December 31, 2022, up from $33,120,924 in the same period of 2021, representing a 33.5% increase[84]. - The company ended the period with cash of $45,748,591, compared to $30,391,675 at the end of December 31, 2021, showing a 50.5% increase in cash reserves[84]. - The net loss per common share (basic and diluted) for the six months ended December 31, 2022, was $(0.89), compared to $(0.45) for the same period in 2021, indicating a 97.8% increase in loss per share[81]. - The company recognized stock-based compensation expenses of $2,591,427 for stock options during the six months ended December 31, 2022, compared to $3,074,384 in the prior year, a decrease of 15.8%[84]. - The total operating expenses for the six months ended December 31, 2022, were $20,329,144, a significant increase from $12,212,294 for the same period in 2021, representing a 66.5% increase[81]. - Research and development expenses rose to $13,802,830 for the six months ended December 31, 2022, compared to $7,808,444 in the prior year, marking a 76.3% increase[81]. - Selling, general and administrative expenses rose to approximately $6.4 million for the six months ended December 31, 2022, compared to $4.3 million in 2021, an increase of approximately $2.1 million[164]. - The net loss for the six months ended December 31, 2022, was approximately $26.1 million, compared to $11.0 million for the same period in 2021, reflecting an increase of approximately $15.1 million[162]. - The Company had cash of approximately $45.7 million and working capital of approximately $38.2 million as of December 31, 2022[166]. Capital Structure and Financing - A loan agreement with Avenue Venture Opportunities Fund provides up to $20 million in growth capital, with $15 million funded as of November 30, 2021, and a maturity date of December 1, 2024[43]. - The loan bears interest at a minimum of 10.75%, with a conversion option allowing Avenue to convert up to $5 million of the loan into shares at a price of $6.98 per share[46]. - Management expects future funding sources may include equity sales, loans, or other strategic transactions[71]. - The company has outstanding warrants to purchase 7,770,285 shares at exercise prices ranging from $1.82 to $12.50 per share[59]. - The company’s loan agreement allows for up to $5 million of the outstanding loan to be converted into shares at a conversion price of $6.98 per share[59]. - The remaining principal balance of $15 million under the Loan is payable in 18 monthly installments starting July 1, 2023, with $10 million due in fiscal year 2024 and $5 million in fiscal year 2025[109]. - The Company sold 4,312,741 shares of common stock for total net proceeds of $32.5 million during the three months ended December 31, 2022[127]. - The Company issued 3,636,364 shares of common stock at $1.65 per share to Acuitas, raising approximately $5.9 million in net proceeds[93]. - The total interest expense for the three months ended December 31, 2022, was approximately $1.1 million, which included interest payments of about $518,000 and an unearned discount of approximately $400,000[108]. - The total change in the fair value of derivative liabilities was approximately $3.2 million for the three months ended December 31, 2022[160]. - The fair value of derivative liabilities, including Avenue Warrants and conversion options, totaled $4,171,113 as of December 31, 2022[138]. - The net notes payable, after accounting for financing costs and discounts, was $13,261,058 as of December 31, 2022, compared to $12,138,686 on June 30, 2022[118]. Intellectual Property and Regulatory Risks - The company has filed a PCT application for novel liquid formulations of terlipressin and holds 15 issued U.S. patents as of December 31, 2022, with ongoing efforts to secure additional patent protections[33]. - There is no assurance that the company's product candidates will obtain regulatory approval, which poses a significant risk to future operations[30]. - The FDA's approval of Mallinckrodt's terlipressin product for hepatorenal syndrome may impact the competitive landscape for BioVie’s BIV201, as it could block approval for seven years due to orphan drug exclusivity[52]. - The patent position of the company is uncertain, and there is no assurance that future patent applications will result in granted patents[222]. - The company may face significant challenges in protecting its proprietary rights in foreign countries where laws may not offer the same protections as in the U.S.[223]. - The company cannot assure investors of its ability to continue innovating and filing new patent applications[222]. - If the company fails to obtain or maintain Orphan Drug exclusivity for BIV201, it may have to rely on other marketing exclusivity and intellectual property rights[218]. - The company relies on a combination of trade secrets, know-how, and contractual agreements to protect its proprietary technologies, which may be at risk if disclosed or independently developed by competitors[223]. - The company faces risks from potential competition from generic versions of its products, which could adversely impact future revenue and profitability[199]. - The company is obligated to issue up to 18 million shares of common stock upon achieving certain clinical, regulatory, and commercial milestones related to drug candidates, which may dilute existing shareholders' interests[226]. Corporate Governance and Legal Matters - The Company holds 67.9% of its issued and outstanding common stock among its directors and executive officers, indicating significant control over corporate decisions[208]. - There were no changes in internal control over financial reporting during the quarter ended December 31, 2022, that materially affected the company's financial reporting[215]. - The company has not been involved in any material legal proceedings or litigation, and there are no judgments against its officers or directors[216].